Literature DB >> 28447063

Lymphadenectomy: how to do it?

Simone Giacopuzzi1, Maria Bencivenga1, Chiara Cipollari1, Jacopo Weindelmayer1, Giovanni de Manzoni1.   

Abstract

According to the more recent European guidelines, the D2 lymphadenectomy is considered the standard for curative intent treatment of patients with gastric cancer. Although, the surgical definition of D2 dissection and its technical aspects had been learned from Eastern surgeons in the past decades, some variations in the approach to D2 lymphadenectomy by European surgeons were detectable in randomized clinical trials dealing with lymphadenectomy. Despite in more recent years an improvement in surgical quality has been reported in European series, some differences in the practice of D2 dissection are thought to persist. As, these may contribute to discrepancies in gastric cancer survival observed across European countries, the standardization of surgical quality is an urgent need to improve the outcome of gastric cancer patients in Europe. In this manuscript, we focus on the technical aspects of the D2 dissection both in open and laparoscopic gastrectomy in order to contribute to the improvement of surgical care of gastric cancer in the West.

Entities:  

Keywords:  D2 lymphadenectomy; Gastric cancer; standardization; surgical technique

Year:  2017        PMID: 28447063      PMCID: PMC5388630          DOI: 10.21037/tgh.2017.03.09

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  17 in total

1.  Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A Okines; M Verheij; W Allum; D Cunningham; A Cervantes
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

2.  Early outcomes from the Dutch Upper Gastrointestinal Cancer Audit.

Authors:  L A D Busweiler; B P L Wijnhoven; M I van Berge Henegouwen; D Henneman; N C T van Grieken; M W J M Wouters; R van Hillegersberg; J W van Sandick
Journal:  Br J Surg       Date:  2016-10-05       Impact factor: 6.939

3.  Changing clinical and pathological features of gastric cancer over time.

Authors:  D Marrelli; C Pedrazzani; P Morgagni; G de Manzoni; F Pacelli; A Coniglio; A Marchet; L Saragoni; S Giacopuzzi; F Roviello
Journal:  Br J Surg       Date:  2011-05-10       Impact factor: 6.939

4.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

5.  Ex Vivo Lymphadenectomy During Gastrectomy for Adenocarcinoma Optimizes Lymph Node Yield.

Authors:  Cheguevara Afaneh; Adam Levy; Luke Selby; Geoffrey Ku; Laura Tang; Sam S Yoon; Daniel Coit; Vivian E Strong
Journal:  J Gastrointest Surg       Date:  2015-09-24       Impact factor: 3.452

Review 6.  Guidelines for the management of oesophageal and gastric cancer.

Authors:  William H Allum; Jane M Blazeby; S Michael Griffin; David Cunningham; Janusz A Jankowski; Rachel Wong
Journal:  Gut       Date:  2011-06-24       Impact factor: 23.059

7.  The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015.

Authors:  Giovanni De Manzoni; Daniele Marrelli; Gian Luca Baiocchi; Paolo Morgagni; Luca Saragoni; Maurizio Degiuli; Annibale Donini; Uberto Fumagalli; Maria Antonietta Mazzei; Fabio Pacelli; Anna Tomezzoli; Mattia Berselli; Filippo Catalano; Alberto Di Leo; Massimo Framarini; Simone Giacopuzzi; Luigina Graziosi; Alberto Marchet; Mario Marini; Carlo Milandri; Gianni Mura; Elena Orsenigo; Vittorio Quagliuolo; Stefano Rausei; Riccardo Ricci; Fausto Rosa; Giandomenico Roviello; Andrea Sansonetti; Giovanni Sgroi; Guido Alberto Massimo Tiberio; Giuseppe Verlato; Carla Vindigni; Riccardo Rosati; Franco Roviello
Journal:  Gastric Cancer       Date:  2016-06-02       Impact factor: 7.370

8.  Indexes of surgical quality in gastric cancer surgery: experience of an Italian network.

Authors:  G Verlato; F Roviello; A Marchet; S Giacopuzzi; D Marrelli; D Nitti; G de Manzoni
Journal:  Ann Surg Oncol       Date:  2009-01-01       Impact factor: 5.344

9.  Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer.

Authors:  M Degiuli; M Sasako; A Ponti; A Vendrame; M Tomatis; C Mazza; A Borasi; L Capussotti; G Fronda; M Morino
Journal:  Br J Surg       Date:  2014-01       Impact factor: 6.939

10.  Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group.

Authors:  A Cuschieri; S Weeden; J Fielding; J Bancewicz; J Craven; V Joypaul; M Sydes; P Fayers
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

View more
  3 in total

1.  Short-term outcomes of D2 lymphadenectomy plus complete mesogastric excision for gastric cancer: a propensity score matching analysis.

Authors:  Dayong Zhao; Jiao Deng; Beibei Cao; Jie Shen; Liang Liu; Aitang Xiao; Ping Yin; Daxing Xie; Jianping Gong
Journal:  Surg Endosc       Date:  2022-05-31       Impact factor: 3.453

2.  Complete mesogastric excision for locally advanced gastric cancer: short-term outcomes of a randomized clinical trial.

Authors:  Daxing Xie; Jie Shen; Liang Liu; Beibei Cao; Yatao Wang; Jichao Qin; Jianhong Wu; Qun Yan; Yuanlong Hu; Chuanyong Yang; Zhixin Cao; Junbo Hu; Ping Yin; Jianping Gong
Journal:  Cell Rep Med       Date:  2021-03-16

3.  The iGreenGO Study: The Clinical Role of Indocyanine Green Imaging Fluorescence in Modifying the Surgeon's Conduct During the Surgical Treatment of Advanced Gastric Cancer-Study Protocol for an International Multicenter Prospective Study.

Authors:  Pietro Maria Lombardi; Michele Mazzola; Vincenzo Nicastro; Simone Giacopuzzi; Gian Luca Baiocchi; Carlo Castoro; Riccardo Rosati; Uberto Fumagalli Romario; Luigi Bonavina; Fabio Staderini; Ines Gockel; Dario Gregori; Paolo De Martini; Monica Gualtierotti; Maria Danieli; Simona Beretta; Massimiliano Mutignani; Edoardo Forti; Giovanni Ferrari
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.